Drug Profile
Olutasidenib - Forma Therapeutics
Alternative Names: FT 2102; REZLIDHIALatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Class Amines; Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia
- Phase I/II Glioma; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 05 Apr 2024 Updated efficacy data from a phase I/II trial in Acute myeloid leukaemia released by Rigel Pharmaceuticals
- 04 Jan 2024 Rigel Pharmaceuticals plans a phase II trial for Glioma (Children, Aadolescents, In adults, First line therapy, Combination Therapy) in Australia, Canada, Germany, Netherlands, United Kingdom and USA (NCT06161974)
- 04 Jan 2024 Rigel Pharmaceuticals and CONNECT agree to co-develop olutasidenib for Glioma